Cameron Turtle, Spyre Therapeutics CEO
November 27, 2023 07:00 AM EST
People

Ex­clu­sive: Ae­glea re­brands to Spyre, names new CEO in IBD race against TL1A drugs at Mer­ck, Roche and Sanofi

Kyle LaHucik

Senior Reporter

Ae­glea Bio­Ther­a­peu­tics will as­sume the name of the drug de­vel­op­er it re­verse merged with ear­li­er this year, Spyre Ther­a­peu­tics, as the biotech fo­cus­es on its …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

A service from the Financial Times